Myositis is a disorder in which the immune system attacks the muscles. It is hoped that this new treatment may help improve the symptoms of this disease.

Research Objectives

Status

Current

Recruitment

Open

Patient Group

Idiopathic Inflammatory Myopathy/Myositis Status: Current

Study location

Wesley Research Institute

Phase

3

Study type

Industry Sponsored

Sponsors: Argenx BV (global) and ICON Clinical Research Pty Ltd (Local)

    Lead investigator    
            Dr Daman Langguth        

        Clinical trial coordinator		
				Venita Bali			

Technical title

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathies

About this research project

The research project is testing a new treatment for Active Idiopathic Inflammatory Myopathy. This is a disorder in which the immune system attacks the muscles. This leads to muscle weakness and may affect other organs of the body.

The potential new treatment being tested is called efgartigimod (also called ARGX113). It is hoped that efgartigimod may help improve the symptoms of myositis.

Latest News & Discoveries

Breakthrough Research Reveals Why Some Cancer Patients Respond to Immunotherapy While Others Don’t

In a groundbreaking study, Australian researchers at the Queensland Spatial Biology Centre (QSBC) have uncovered a crucial factor that determines whether patients with head and neck cancer will respond to immunotherapy - a finding that could pave the way for more effective treatments and improved survival rates. 

New Research Highlights the Potential of Private Virtual Hospitals to Improve Healthcare Access

New research has revealed the immense potential of private virtual hospitals to transform healthcare delivery in Australia. The study explores how these “hospitals without walls” can safely and effectively provide hospital-level care in patients’ homes, combining telehealth consultations, remote monitoring, and hybrid care approaches.

Wesley Research Institute’s First Coeliac Disease Webinar Series A Success

Wesley Research Institute’s inaugural Coeliac Disease Webinar Series has been met with an overwhelming response. The two-session event - one tailored for individuals living with coeliac disease and the other for clinicians - featured leading experts Dr James Daveson, Clinical Director of the Coeliac Research and Immune Health Program at Wesley Research Institute, and Dr Jason W. Chien, Chief Medical Officer at Mozart Therapeutics.

1 2 3 … 19 Next »

Rare Diseases

Testing treatments to improve symptoms of Myositis